Literature DB >> 376572

Comparison of four weeks' treatment with fenoterol and terbutaline aerosols in adult asthmatics. A double-blind crossover study.

P W Trembath, J K Greenacre, M Anderson, S Dimmock, L Mansfield, J Wadsworth, M Green.   

Abstract

Fenoterol and terbutaline, two long-acting beta 2-adrenoceptor agonists in aerosol form, were compared in an 8-wk randomized double-blind crossover study in 22 mild to moderately severe asthmatics. Patients completed diary cards, recorded peak expiratory flow rate (PEFR) twice daily, and attended a clinic for measurement of PEFR, 1-sec forced expiratory volume (FEV1), and forced vital capacity (FVC) twice during each treatment period. Fifteen patients completed the study; 5 dropped out while using fenoterol, and 2 while using terbutaline. At clinic attendances, the patients had a significantly higher mean PEFR after 4 wk on terbutaline (385 L/min) than after fenoterol (316 L/min) (p less than 0.001). Similar results were found on analysis of the morning and evening PEFR recordings. On comparing each individual's PEFR recordings during the 2 treatments, it was found that there was no significant difference among the treatments in 3 patients, while 9 patients had a better response to terbutaline, and 3 patients had a better response to fenoterol. While similar number expressed a subjective preference for each treatment, the lung function data suggested that the effectiveness of fenoterol appeared to decline during the trial period.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 376572     DOI: 10.1016/0091-6749(79)90212-4

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  8 in total

Review 1.  Long- versus short-acting beta 2-agonists. Implications for drug therapy.

Authors:  L P Boulet
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

Review 2.  Asthma and the beta agonist debate.

Authors:  J Crane; N Pearce; C Burgess; R Beasley
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

3.  Beta agonists and ventilation.

Authors:  A E Tattersfield; P Wilding
Journal:  Thorax       Date:  1993-09       Impact factor: 9.139

4.  Effect of oral slow-release terbutaline on early morning dyspnoea.

Authors:  G H Koëter; D S Postma; J J Keyzer; H Meurs
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study.

Authors:  J Grainger; K Woodman; N Pearce; J Crane; C Burgess; A Keane; R Beasley
Journal:  Thorax       Date:  1991-02       Impact factor: 9.139

6.  Effect of regular terbutaline on the airway response to inhaled budesonide.

Authors:  P J Wilding; M M Clark; J Oborne; J A Bennett; A E Tattersfield
Journal:  Thorax       Date:  1996-10       Impact factor: 9.139

7.  Regular inhaled beta agonist in asthma: effects on exacerbations and lung function.

Authors:  D R Taylor; M R Sears; G P Herbison; E M Flannery; C G Print; D C Lake; D M Yates; M K Lucas; Q Li
Journal:  Thorax       Date:  1993-02       Impact factor: 9.139

Review 8.  The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology.

Authors:  M R Sears; D R Taylor
Journal:  Drug Saf       Date:  1994-10       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.